Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Chromosomal rearrangements of the anaplastic lymphoma kinase (ALK) gene occur in 3-5% of non-small cell lung cancer (NSCLC).
• Crizotinib, a first-in-class ALK tyrosine kinase inhibitor, demonstrated efficacy in ALK-positive NSCLC, advancing personalized medicine.
• While crizotinib offers rapid and durable responses, acquired resistance limits long-term efficacy.

Purpose of the Study:

• To review the therapeutic landscape of ALK-positive NSCLC.
• To highlight the challenges posed by acquired resistance to crizotinib.
• To discuss emerging therapeutic strategies targeting ALK-positive NSCLC.

Main Methods:

• Review of clinical trial data for crizotinib in ALK-positive NSCLC.
• Analysis of mechanisms of acquired resistance to ALK inhibitors.
• Evaluation of novel therapeutic agents in clinical development.

Main Results:

• Crizotinib demonstrated superiority over chemotherapy in previously treated ALK-positive NSCLC patients.
• The majority of patients initially respond to crizotinib, but acquired resistance is common.
• Several second-generation ALK inhibitors and heat shock protein 90 inhibitors are under investigation.

Conclusions:

• Targeted therapy for ALK-positive NSCLC has significantly impacted treatment paradigms.
• Overcoming acquired resistance is a critical challenge in managing ALK-positive NSCLC.
• Ongoing research into novel inhibitors and combination therapies holds promise for improving patient outcomes.